


Thursday | 22 October 2026 | 12:00 – 13:00Convention & Exhibition Center (COEX) | Seoul, Korea
Grand Ballroom 103**LUNCH
PACKAGE
FOR FREE**

Bringing Science to the Bedside: Clinically Proven Cerebroprotection in AIS

Chair: **Kwang-Yeol Park (Korea)**Co-Chair: **Michael Brainin (Austria)****Steven Zeiler (USA)**Can Cerebroprotective Agents Improve BBB Integrity in AIS?
New Imaging Study Results**Peter Lackner (Austria)**

How Does the CREGS Study Benefit Routine Clinical Practice?

*Visit our Satellite Symposium and receive a copy of "Outcomes II"**Remarkable Cases in Cerebroprotection and Neurorecovery. A collection of practice-based evidence cases in Stroke, TBI and other neurological disorders.*

SMALL MOMENT. BIG DIFFERENCE.

Last month, Paul was suffering from cognitive and motor impairment.
Today, he's making his next big move.

- Early and sustained functional recovery
- Enhances the effects of recanalization therapy
- Effective as stand-alone therapy
- Preserves cognitive functions

Vosko et al., 2025

ABBREVIATED PRESCRIBING INFORMATION: Name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.



Cerebrolysin®

**Reconnecting Neurons.
Empowering for Life.**